MOTS-c in Canada: A Research Guide to the Mitochondrial-Derived Metabolic Peptide

Why MOTS-c deserves its own research guide#

MOTS-c Canada searches are rising because the peptide occupies a genuinely unusual position in the metabolic research landscape. Unlike Semaglutide, which acts through the well-characterised GLP-1 receptor axis, or AOD-9604, which targets adipose lipolysis via beta-3-adrenergic pathways, MOTS-c is a mitochondrial-derived signalling molecule. It is encoded in the mitochondrial genome, translated in the cytoplasm, and translocates to the nucleus under metabolic stress to reprogram nuclear gene expression. That mechanism places it at the intersection of mitochondrial biology, exercise physiology, metabolic disease, and aging research.

Northern Compound places MOTS-c in the weight-management archive because the dominant search intent is metabolic: researchers want to understand how this peptide influences glucose disposal, insulin sensitivity, fat oxidation, and body composition. But the responsible framing is not narrow. MOTS-c also appears in longevity research, cardiovascular studies, and diabetes prevention models. A good guide should explain the full mechanistic picture, the strength of the preclinical evidence, the status of human clinical development, and the practical sourcing considerations that apply to a peptide with this specific research identity.

This article treats MOTS-c as research-use-only material. It does not provide dosing instructions, injection guidance, diabetes-treatment advice, or personal-use recommendations. The purpose is to map the evidence, clarify the mechanism, distinguish MOTS-c from other metabolic peptides, and set sourcing standards that match its actual research history.

What MOTS-c is at the molecular level#

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame (sORF) within the mitochondrial 12S rRNA gene (mt-RNR1). The full sequence is:

Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

This corresponds to residues 1382–1421 of the human mitochondrial genome, reading in the heavy-strand direction. The peptide was identified in 2015 by Changhan Lee, Nils Storm, and colleagues at the USC Leonard Davis School of Gerontology, who systematically searched mitochondrial genomes for evolutionarily conserved sORFs that might yield bioactive peptides.

The first 11 residues of MOTS-c are highly conserved across at least 14 mammalian species, including humans, mice, rats, and rhesus monkeys. That degree of phylogenetic conservation suggests strong selective pressure and functional importance. Notably, a mitochondrial DNA single-nucleotide polymorphism (m.1382A>C) found in an exceptionally long-lived Japanese population produces a functional MOTS-c variant with a lysine-to-glutamine substitution at position 14 (K14Q), linking MOTS-c genetics to human longevity phenotypes.

A unique bi-genomic origin#

Unlike the vast majority of mitochondrial proteins, which are translated inside mitochondria on mitochondrial ribosomes using the mitochondria-specific genetic code, MOTS-c is translated in the cytoplasm on standard 80S ribosomes using the universal genetic code. This is necessary because the mitochondrial genetic code interprets the AGA and AGG codons within the MOTS-c open reading frame as stop codons rather than arginine codons. The mitochondrial transcript is exported from the organelle, polyadenylated, and then translated in the cytosol.

This cytoplasmic translation creates a spatial separation between the peptide's site of synthesis and its site of primary action. MOTS-c can therefore function as an endocrine signal—a mitokine—circulating to distal tissues and mediating inter-organ communication between mitochondria and the nucleus.

Structural and analytical considerations#

MOTS-c is a small, cationic peptide with a molecular weight of approximately 2174 Da. It contains no disulfide bonds, no glycosylation sites, and no post-translational modifications in its mature form. For analytical verification, the minimum supplier package should include:

1. Batch-specific HPLC purity with peak integration, method conditions, and lot number. Given the peptide's small size and basic character, reversed-phase chromatography with an acidic mobile phase (typically TFA or formic acid) is the standard analytical method.
2. Mass spectrometry identity confirmation showing the expected molecular ion at approximately 2174 Da. Electrospray ionisation (ESI) or MALDI-TOF are both acceptable; ESI-MS/MS can additionally confirm sequence.
3. Sequence verification by tandem MS (MS/MS) or Edman degradation, confirming the exact 16-residue sequence.
4. Fill amount documentation stating the net peptide content per vial, not merely the total lyophilisate mass.
5. Endotoxin testing with a stated limit, typically < 5 EU/g or < 0.5 EU/vial for research-grade material.
6. Sterility confirmation where claimed, with method and acceptance criteria.
7. Storage and stability guidance appropriate for a small basic peptide: lyophilised, protected from light, stored at -20 °C or below.

Researchers should not accept a vial labelled simply "mitochondrial peptide" without sequence specification. The mitochondrial-derived peptide family now includes multiple members (humanin, SHLPs, MOTS-c, and others), and cross-contamination or mislabelling between related sequences is a documented risk in grey-market supply chains.

Mechanism: AMPK activation and metabolic reprogramming#

The central mechanistic claim for MOTS-c is that it activates AMP-activated protein kinase (AMPK) in skeletal muscle and other metabolically active tissues, thereby promoting glucose uptake, enhancing insulin sensitivity, and reprogramming cellular metabolism toward improved energy homeostasis. This claim is supported by a robust preclinical literature and is the defining feature that separates MOTS-c from incretin-based compounds, GH secretagogues, and hGH fragments.

AMPK as the primary effector#

AMPK is a heterotrimeric serine/threonine kinase that acts as a cellular energy sensor. When the AMP:ATP ratio rises—during exercise, nutrient deprivation, or metabolic stress—AMPK phosphorylates downstream targets that increase catabolism and suppress anabolism. In skeletal muscle, AMPK activation promotes GLUT4 translocation to the plasma membrane, increasing glucose uptake independently of insulin signalling. It also stimulates fatty acid oxidation and mitochondrial biogenesis through PGC-1α phosphorylation.

Lee et al. (2015) demonstrated that MOTS-c treatment increases AMPK phosphorylation (Thr172) in C2C12 myotubes and in mouse skeletal muscle. The effect is dose-dependent and correlates with increased glucose uptake and improved insulin sensitivity in high-fat-diet-fed mice. Pharmacological AMPK inhibition blocks MOTS-c's metabolic effects, confirming that AMPK is a required mediator rather than a coincidental marker.

Nuclear translocation and transcriptional reprogramming#

Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus in an AMPK-dependent manner. Once in the nucleus, it binds to transcription factors associated with antioxidant response elements (AREs) and modulates the expression of stress-resistance genes. Reynolds et al. (2021) showed that exogenous MOTS-c dynamically accumulates in the nucleus of C2C12 myoblasts under glucose restriction, and that nuclear MOTS-c regulates heat-shock response genes through heat-shock factor 1 (HSF1).

This nuclear role is functionally important. siRNA-mediated HSF1 knockdown reverses MOTS-c's protective effects against metabolic stress in myoblasts, demonstrating that the transcriptional programme is not merely correlative but causally required for the peptide's cellular benefits. The regulated gene sets include metabolic enzymes, proteostasis machinery, oxidative-stress defences, and immune-modulatory factors.

Mitochondrial-to-nuclear signalling#

MOTS-c exemplifies a broader biological phenomenon: mitonuclear communication. The mitochondrial and nuclear genomes co-evolved, and their integration is essential for cellular adaptation. By encoding a signalling peptide within the mitochondrial genome that translocates to the nucleus to regulate nuclear genes, MOTS-c provides a direct molecular mechanism for mitochondrial feedback control of cellular transcription.

This mitonuclear signalling framework is relevant to aging research. The mitochondrial theory of aging posits that accumulated mitochondrial DNA mutations impair oxidative phosphorylation and drive cellular senescence. MOTS-c levels decline with age in both mice and humans, and restoring MOTS-c in aged animals improves metabolic function and physical performance. The peptide therefore represents a potential intervention point for mitonuclear ageing biology, not merely for acute metabolic modulation.

Distinction from other metabolic peptide mechanisms#

Modern weight-management research is dominated by GLP-1, GIP, and glucagon receptor agonism. Semaglutide and tirzepatide work primarily through appetite suppression, delayed gastric emptying, and central satiety signalling. AOD-9604 acts on adipose tissue lipolysis, potentially via beta-3-adrenergic receptors. MOTS-c does none of these things. It does not bind the GLP-1 receptor, the ghrelin receptor, or the beta-3-AR. It acts intracellularly through AMPK and nuclear transcription factors, making it mechanistically orthogonal to every major commercial weight-management peptide.

For researchers comparing peptide approaches to metabolic research, that orthogonality is more important than any surface similarity in catalogue category. MOTS-c is relevant for mitochondrial biology, exercise mimetics, insulin-sensitivity models, and aging-related metabolic decline. GLP-1 agonists are relevant for neuroendocrine appetite regulation and incretin physiology. The two should not be conflated.

Preclinical evidence: obesity, insulin resistance, and exercise performance#

The preclinical literature on MOTS-c is substantial and growing. Since its discovery in 2015, multiple independent groups have confirmed and extended the original findings in rodent models of metabolic disease, aging, and physical performance.

High-fat-diet-induced obesity and insulin resistance#

Lee et al. (2015), published in Cell Metabolism, is the foundational paper. The researchers treated C57BL/6 mice fed a high-fat diet (60% calories from fat) with daily intraperitoneal MOTS-c injections. After seven days, treated mice showed:

• Significantly improved glucose tolerance during intraperitoneal glucose tolerance tests (IPGTT).
• Reduced fasting insulin levels and improved HOMA-IR indices.
• Prevention of diet-induced weight gain without affecting food intake.
• Normalisation of hepatic steatosis markers.

Critically, MOTS-c did not affect body weight or glucose metabolism in mice fed a standard chow diet. This selectivity for metabolically stressed animals is pharmacologically important: it suggests that MOTS-c acts as a homeostatic correction signal rather than a general anorexic or hypoglycaemic agent.

The mechanism was confirmed to be AMPK-dependent. In skeletal muscle isolated from treated mice, AMPK phosphorylation was increased, and GLUT4 membrane translocation was enhanced. In vitro, MOTS-c increased glucose uptake in L6 myotubes and C2C12 myotubes, and this effect was blocked by the AMPK inhibitor compound C.

Exercise-mimetic and performance-enhancing effects#

Reynolds et al. (2021), published in Nature Communications, established MOTS-c as an exercise-induced mitokine with performance-enhancing properties. Key findings include:

• Human exercise data: In sedentary healthy young males, stationary-bicycle exercise increased skeletal-muscle MOTS-c levels 11.9-fold post-exercise, with elevation persisting for four hours. Plasma MOTS-c increased 1.6-fold during exercise and 1.5-fold post-exercise.

• Young mice (2 months): Daily MOTS-c (15 mg/kg IP) for two weeks significantly improved treadmill running performance. One hundred percent of high-dose mice reached the final sprint stage (23 m/min) versus 16.6% of controls. High-dose MOTS-c also retarded fat gain and increased lean mass (NMR analysis).

• Old mice (22 months): The same treatment protocol restored treadmill performance to levels exceeding those of untreated middle-aged mice. Old mice ran approximately 2-fold longer and 2.16-fold farther. Metabolic flexibility, measured by circadian respiratory exchange ratio (RER), was restored to middle-aged patterns.

• Late-life intermittent treatment: MOTS-c initiated at 23.5 months of age (intermittent 3×/week dosing) significantly improved grip strength, gait, and walking distance at >30 months. Median lifespan trended toward a 6.4% increase (hazard ratio 0.654; log-rank P = 0.05 until 31.8 months).

These data position MOTS-c as a genuine exercise mimetic—a compound that activates the same molecular pathways as endurance exercise and produces overlapping physiological benefits. The distinction from anabolic agents or stimulants is important: MOTS-c does not increase heart rate, blood pressure, or sympathetic tone in the models tested. Its effects are metabolic and transcriptional rather than cardiovascular or neurological.

Aging and cellular senescence#

Recent work has extended MOTS-c into senescence biology. A 2025 paper in Experimental & Molecular Medicine showed that MOTS-c levels decline dramatically with age in mouse pancreatic beta-cells and in human tissues. In 90-week-old C57BL/6 mice, beta-cell MOTS-c was approximately 14-fold lower than in 12-week-old mice. Systemic MOTS-c administration prevented beta-cell senescence and delayed diabetes onset in three independent rodent models: chronologically aged mice, NOD type-1-diabetes mice, and insulin-receptor-antagonist (S961)-treated mice.

The mechanism involves mTORC1 inhibition and suppression of glutaminolysis-dependent senescence. MOTS-c overexpression in Min6 beta-cells increased nuclear MOTS-c under oxidative stress, reduced mTORC1 activity (measured by p4E-BP1 and pS6), and downregulated senescence-associated secretory phenotype (SASP) markers including IL-1β and Cxcl10. In the S961 model, MOTS-c co-treatment reduced diabetes incidence from 70% to 30%.

These findings connect MOTS-c to two major longevity pathways: AMPK (a negative regulator of mTORC1) and mTORC1 itself. The peptide appears to sit at a signalling node that coordinates mitochondrial status with cellular growth, stress resistance, and senescence decisions.

Cardiovascular and endothelial effects#

MOTS-c has also been studied in cardiovascular contexts. Zheng et al. (2023), in Frontiers in Endocrinology, reviewed evidence that MOTS-c protects coronary artery endothelial cell function, improves angiogenesis, and reduces apoptosis in cardiac cells through AMPK pathway activation and NF-κB suppression. In diabetic rats, MOTS-c restored cardiac function through NRG1-ErbB signalling pathway modulation.

The cardiovascular data are less developed than the metabolic literature, but they suggest that MOTS-c's tissue-protective effects extend beyond skeletal muscle and adipose tissue. For researchers designing multi-system metabolic studies, this breadth is relevant.

Human clinical development: from preclinical models to Phase 2a#

As of April 2026, MOTS-c has no regulatory approvals for human therapeutic use in any jurisdiction. Health Canada has not approved it. The FDA has not approved it. The EMA has not approved it. However, human clinical development is now underway, which distinguishes MOTS-c from many research peptides that have never advanced beyond rodent models.

Phase 2a clinical trial (NCT07505745)#

In February 2026, Hudson Biotech initiated a Phase 2a, randomised, double-blind, placebo-controlled trial evaluating MOTS-c for improving insulin sensitivity in adults with prediabetes and overweight/obesity. The trial details are:

• Design: Two-arm, multicentre, parallel-group, quadruple-masked (participant, care provider, investigator, outcomes assessor).
• Allocation: 1:1 randomisation to MOTS-c or matching placebo.
• Population: Adults aged 18–65 years, BMI 27.0–40.0 kg/m², with documented prediabetes (HbA1c 5.7–6.4%, fasting glucose 100–125 mg/dL, or 2-hour glucose 140–199 mg/dL on OGTT).
• Intervention: Subcutaneous injection once daily for 12 weeks, plus standardised lifestyle counselling.
• Primary endpoints: Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index) at 12 weeks; incidence of treatment-emergent adverse events over 16 weeks.
• Secondary endpoints: Changes in HbA1c, fasting glucose, 2-hour OGTT glucose, and immunogenicity (anti-drug antibodies).
• Estimated enrolment: 120 participants.
• Primary completion: Estimated February 2027.

This trial is the first formal human efficacy study of MOTS-c for metabolic endpoints. If the Matsuda Index improvement reaches statistical significance, it would provide the first clinical proof-of-concept that mitochondrial-derived peptides can modulate human insulin sensitivity. If the trial fails to meet its primary endpoint, it would join AOD-9604 as an example of promising preclinical data that did not translate robustly into human metabolic outcomes.

Earlier human data#

Before the Phase 2a programme, published human data on MOTS-c were limited to observational biomarker studies. Reynolds et al. (2021) measured endogenous MOTS-c in healthy young males and showed exercise-induced increases, confirming that the peptide is physiologically regulated in humans. Several cross-sectional studies have reported lower circulating MOTS-c in older adults, in type-2-diabetes patients, and in sedentary populations compared with healthy active controls.

These observational data are consistent with the rodent findings but do not establish causality. The Phase 2a trial is therefore a critical inflection point for the field.

Metabolic distinctions: MOTS-c versus GLP-1 agonists, GH secretagogues, and hGH fragments#

Canadian researchers often encounter MOTS-c in catalogues that also list GLP-1 peptides, growth-hormone peptides, and metabolic fragments. Understanding where MOTS-c fits requires comparing it with its nearest mechanistic neighbours.

This table highlights why MOTS-c should not be treated as a "milder semaglutide" or as a substitute for GH secretagogues or hGH fragments. The receptor biology, downstream signalling, tissue targets, and risk profile are entirely distinct.

Canadian RUO context and compliance language#

For Canadian labs, the regulatory landscape for MOTS-c is straightforward in principle but often blurred in practice. The compound is not a Health Canada-approved drug. It is not a natural health product. It is not a dietary supplement. It is a synthetic mitochondrial-derived peptide with an active Phase 2a clinical trial but no marketing authorisation.

Research-use-only means laboratory research. It does not mean personal experimentation, gym use, or anti-aging self-administration. Canadian researchers should expect suppliers to:

• Label the product explicitly as research-use-only.
• Avoid therapeutic claims, dosing instructions, or human-use guidance.
• Provide batch-specific analytical documentation.
• Ship with appropriate stability and storage instructions.
• Include a safety data sheet (SDS) for laboratory handling.

Northern Compound's broader Canadian research peptide buyer's guide covers supplier evaluation in detail. For MOTS-c specifically, the due-diligence checklist should emphasise sequence verification and endotoxin testing, because mitochondrial-derived peptides are sometimes synthesised by less rigorous suppliers who conflate them with other small basic peptides such as humanin fragments or SHLPs.

Sourcing MOTS-c: COA, purity, and analytical expectations#

Because MOTS-c is a defined-sequence synthetic peptide without post-translational modifications, its analytical requirements are standard but must be applied rigorously.

Minimum COA expectations#

1. HPLC purity: A reversed-phase chromatogram showing the principal peak, integration percentage, method conditions, and lot number. Purity should be reported as the peptide peak area percentage, with clear identification of any significant impurities.
2. Mass spectrometry: Electrospray ionisation MS or MALDI-TOF confirming the expected molecular weight of approximately 2174 Da. If the material is supplied as a salt (e.g., acetate or TFA salt), the COA should specify the counter-ion and the corresponding molecular weight.
3. Sequence verification: Tandem MS (MS/MS) or Edman degradation data confirming the exact 16-amino-acid sequence.
4. Fill amount: The vial should state the net peptide content, not just the total mass of lyophilised powder. Excipients such as mannitol should be listed if present.
5. Residual solvent and water content: Residual TFA, acetonitrile, or ether levels should be within acceptable limits for solid-phase synthesis products.
6. Endotoxin: A stated limit, typically < 5 EU/g or lower, with method (LAL chromogenic or gel-clot).
7. Sterility: Where claimed, method and acceptance criteria should be documented.
8. Storage and stability data: Guidance on reconstitution, shelf life, and recommended storage temperature.

Supplier red flags#

• A product labelled only "mitochondrial peptide" without sequence specification.
• A COA that reports only total lyophilisate mass, not net peptide content.
• Absence of mass spectrometry or sequence data.
• Claims about fat loss, muscle gain, or anti-aging results on the product page.
• Pricing or packaging oriented toward consumer rather than laboratory use.
• Confusion with related peptides such as humanin, SHLP2, or SHLP3.

Lynx Labs lists MOTS-c in the weight-management category and is the domestic supplier Northern Compound currently points readers toward for Canadian research-source evaluation. That recommendation is based on the same criteria applied elsewhere: batch documentation, domestic fulfilment, product-category clarity, and attribution-transparent outbound links. Researchers should still verify the current lot's COA before using any material in an experiment.

Comparison with modern weight-management peptides#

MOTS-c is frequently compared with GLP-1-based compounds in online discussions, but the comparison is mechanistically weak. The table below clarifies the research positioning.

For Canadian researchers designing metabolic studies, the choice between MOTS-c and other peptides should be driven by the experimental question. MOTS-c is relevant for mitochondrial biology, AMPK signalling, exercise mimetics, and insulin-sensitivity models. GLP-1 agonists are relevant for neuroendocrine appetite regulation and incretin physiology. AOD-9604 is relevant for adipose-tissue-specific lipolysis research.

Designing better MOTS-c studies#

A high-quality MOTS-c study should exploit the compound's specific features rather than treating it as a generic "metabolic peptide." Because clinical development is in early Phase 2a, there is no pending regulatory filing to align with, and researchers have considerable freedom to explore mechanistic questions.

Skeletal muscle mechanistic studies#

The AMPK/GLUT4 axis is the strongest validated mechanism. A well-designed study should measure:

• AMPK phosphorylation (Thr172) and downstream ACC phosphorylation in skeletal muscle.
• GLUT4 membrane translocation or total GLUT4 protein expression.
• Glucose uptake in isolated muscle strips or cultured myotubes.
• Metabolomics profiling of glycolytic intermediates, TCA cycle metabolites, and acylcarnitines.

A study that measures only body weight or food intake misses the mechanistic layer entirely.

Exercise-comparison and synergy designs#

Because MOTS-c is described as an exercise mimetic, a strong protocol would compare MOTS-c treatment with treadmill training and with combined MOTS-c plus training. The hypothesis would be whether the peptide produces additive, synergistic, or redundant effects relative to exercise itself. Endpoints should include treadmill performance, muscle oxidative enzyme activity (e.g., citrate synthase, cytochrome c oxidase), and muscle metabolomics.

Age-stratified designs#

MOTS-c levels decline with age, and the peptide restores function in old mice. A study that stratifies by age—or uses aged rodent models—can test whether MOTS-c's effects are larger in older, MOTS-c-depleted animals than in young, replete animals. This mirrors the clinical trial design logic of testing a compound in the population most likely to benefit.

Metabolic safety monitoring#

Although MOTS-c was well tolerated in rodent toxicology studies, any compound that activates AMPK and influences glucose metabolism can theoretically affect hepatic gluconeogenesis, cardiac metabolism, or renal energy status. A comprehensive protocol includes fasting glucose, insulin, lipid panels, liver enzymes, and body-composition analysis (DEXA or NMR) at baseline and follow-up.

Combination with other peptides#

Some researchers have proposed combining MOTS-c with GLP-1 agonists or with AOD-9604. These combinations are theoretically interesting because the mechanisms are orthogonal, but they are also more complex. A combination study should include single-agent arms for both compounds to isolate synergistic from additive effects, and it should measure more endpoints than either single-agent study alone.

Common mistakes in MOTS-c interpretation#

The first mistake is treating MOTS-c as a "natural" or "safe" alternative to pharmaceutical metabolic agents because it is encoded in the mitochondrial genome. The mitochondrial origin is scientifically interesting, but it does not confer inherent safety. MOTS-c is a pharmacologically active peptide that modulates major energy-sensing pathways. Its safety profile in humans is not yet established beyond the early Phase 2a trial.

The second mistake is assuming that exercise-mimetic effects in mice guarantee athletic-performance benefits in humans. Rodent treadmill data are valuable for mechanistic hypothesis generation, but they do not translate directly to human exercise physiology. VO₂ max, lactate threshold, and skeletal-muscle fibre-type composition differ substantially between species.

The third mistake is conflating "improved insulin sensitivity in prediabetic mice" with "treatment for type 2 diabetes." The preclinical data are promising, but diabetes is a chronic, multi-system disease. No peptide with only rodent data should be presented as a therapeutic substitute for established diabetes management.

The fourth mistake is ignoring the distinction between endogenous and exogenous MOTS-c. Exercise naturally increases skeletal-muscle and circulating MOTS-c. Exogenous administration bypasses the physiological regulatory context. The two are not pharmacologically equivalent.

The fifth mistake is using product-page copy as a primary literature source. Supplier descriptions may cite the Lee (2015) or Reynolds (2021) papers without explaining the limitations of the preclinical data or the early stage of human development. Researchers should read the original papers and monitor ClinicalTrials.gov for trial updates.

The sixth mistake is accepting material labelled only "mitochondrial peptide" without sequence confirmation. The mitochondrial-derived peptide family includes multiple distinct sequences, and mislabelling between related compounds is a known risk.

References and further reading#

• Lee C. et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism (2015). PubMed.
• Reynolds J.C. et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications (2021). DOI.
• Zheng Y., Wei Z., Wang T. "MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation." Frontiers in Endocrinology (2023). DOI.
• Kim J. et al. "Mitochondrial-encoded peptide MOTS-c prevents pancreatic β-cell senescence to delay diabetes." Experimental & Molecular Medicine (2025). DOI.
• ClinicalTrials.gov. "NCT07505745: MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity." ClinicalTrials.gov.
• Lu H. et al. "MOTS-c interacts synergistically with exercise intervention to improve lipid metabolism in high-fat-diet-induced obese mice." Molecular and Cellular Biochemistry (2022). DOI.
• Fuku N. et al. "The mitochondrial-derived peptide MOTS-c and KL vs. QB polymorphism in mtDNA in longevity and healthspan." Journal of Physiological Anthropology (2015). DOI.
• World Anti-Doping Agency. Prohibited List. Current edition. WADA.